Evogene (EVGN) Total Liabilities (2016 - 2025)

Evogene (EVGN) has disclosed Total Liabilities for 10 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 67.75% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Dec 2025, down 67.75% year-over-year, with the annual reading at $8.1 million for FY2025, 67.75% down from the prior year.
  • Total Liabilities hit $8.1 million in Q4 2025 for Evogene, down from $25.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $28.2 million in Q4 2022 to a low of $8.1 million in Q4 2025.
  • Historically, Total Liabilities has averaged $21.3 million across 5 years, with a median of $22.7 million in 2021.
  • Biggest five-year swings in Total Liabilities: rose 24.48% in 2022 and later plummeted 67.75% in 2025.
  • Year by year, Total Liabilities stood at $22.7 million in 2021, then grew by 24.48% to $28.2 million in 2022, then fell by 20.5% to $22.4 million in 2023, then grew by 11.64% to $25.0 million in 2024, then tumbled by 67.75% to $8.1 million in 2025.
  • Business Quant data shows Total Liabilities for EVGN at $8.1 million in Q4 2025, $25.0 million in Q4 2024, and $22.4 million in Q4 2023.